MARA BACTAD: Open Payments
NPI 1164157913 · OXNARD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$968 in 25 payments from 9 companies in 2025. Trend: 2023 $483 · 2024 $1,069 · 2025 $968
Food & beverage: $968
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $296 |
| Edwards Lifesciences Corporation | 2 | $178 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $125 |
| Merck Sharp & Dohme LLC | 4 | $107 |
| Novo Nordisk Inc | 4 | $105 |
| Amgen Inc. | 3 | $72 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $31 |
| ABIOMED | 1 | $30 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
Products named: SAPIEN 3 Ultra RESILIA, Kerendia, LOKELMA, VERQUVO, Wegovy, BREZTRI, Repatha, FARXIGA.
Industry payments across CA — which companies pay providers there.
